These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7717931)

  • 21. A liposome model to treat pseudomonas in lungs of cystic fibrosis and immune compromised patients.
    Yatvin MB
    Cell Mol Biol Lett; 2002; 7(2):304. PubMed ID: 12097974
    [No Abstract]   [Full Text] [Related]  

  • 22. Aminoglycoside ototoxicity susceptibility in cystic fibrosis.
    Mulrennan SA; Helm J; Thomas RB; Dodd M; Jones A; Webb K
    Thorax; 2009 Mar; 64(3):271-2. PubMed ID: 19252031
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical presentation of metabolic alkalosis in an adult patient with cystic fibrosis.
    Sweetser LJ; Douglas JA; Riha RL; Bell SC
    Respirology; 2005 Mar; 10(2):254-6. PubMed ID: 15823195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on treatment of pulmonary exacerbations in cystic fibrosis.
    Smyth A
    Curr Opin Pulm Med; 2006 Nov; 12(6):440-4. PubMed ID: 17053495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Daily single-dose aminoglycoside administration. Therapeutic and economic benefits].
    Knudsen LM; Frimodt-Møller N; Hansen MT; Hippe E
    Ugeskr Laeger; 1993 May; 155(19):1436-41. PubMed ID: 8316969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cystic fibrosis: current therapy. Antibiotics].
    Tamm M; Héritier F; Rappaz I; Schaad UB
    Schweiz Med Wochenschr Suppl; 2000; 122():33S-37S. PubMed ID: 12536469
    [No Abstract]   [Full Text] [Related]  

  • 27. [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection].
    Mordasini C; Aebischer CC; Schoch OD
    Schweiz Med Wochenschr; 1997 May; 127(21):905-10. PubMed ID: 9289818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once daily dosing of aminoglycosides.
    Denaro C
    Aust N Z J Med; 1994 Dec; 24(6):730-1. PubMed ID: 7717932
    [No Abstract]   [Full Text] [Related]  

  • 29. Cystic fibrosis and the pseudomonads.
    Wright KC
    Br J Biomed Sci; 1996 Jun; 53(2):140-5. PubMed ID: 8757691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A ten year review of colomycin.
    Littlewood JM; Koch C; Lambert PA; Høiby N; Elborn JS; Conway SP; Dinwiddie R; Duncan-Skingle F
    Respir Med; 2000 Jul; 94(7):632-40. PubMed ID: 10926333
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacodynamics of tobramycin in patients with cystic fibrosis.
    Mouton JW; Jacobs N; Tiddens H; Horrevorts AM
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis.
    Faruqi S; McCreanor J; Moon T; Meigh R; Morice AH
    Int J Antimicrob Agents; 2008 Nov; 32(5):461-3. PubMed ID: 18703318
    [No Abstract]   [Full Text] [Related]  

  • 33. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
    Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
    Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fosfomycin--investigation of a possible new route of administration of an old drug. A case study.
    Cree M; Stacey S; Graham N; Wainwright C
    J Cyst Fibros; 2007 May; 6(3):244-6. PubMed ID: 17055346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
    Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
    J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of resistant Pseudomonas aeruginosa with elective and rescue intravenous antibiotic regimens in children with cystic fibrosis.
    Smyth E; David TJ; Patel L; Ashcroft P; Sanyal D; Vyas J
    Int J Antimicrob Agents; 2005 Jul; 26(1):95-6. PubMed ID: 15970432
    [No Abstract]   [Full Text] [Related]  

  • 38. [Macrolides, Pseudomonas aeruginosa and cystic fibrosis].
    Guillot M; Amiour M; El Hachem C; Harchaoui S; Ribault V; Paris C
    Arch Pediatr; 2006 Oct; 13 Suppl 1():S48-50. PubMed ID: 17370396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nebulised antipseudomonal therapy in cystic fibrosis.
    Touw DJ; Bakker W
    Thorax; 1996 Dec; 51(12):1283. PubMed ID: 8994535
    [No Abstract]   [Full Text] [Related]  

  • 40. Systematic reviews and lifelong diseases.
    Elphick HE; Tan A; Ashby D; Smyth RL
    BMJ; 2002 Aug; 325(7360):381-4. PubMed ID: 12183313
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.